CA Patent

CA2752150A1 — Selective kinase inhibitors

Assigned to Synerga Ltd · Expires 2010-08-19 · 16y expired

What this patent protects

The present invention relates to methods of modulating (for example, inhibiting) activity of JAK3, comprising con-tacting the JAK3 with a compound of Formula I or pharmaceutically acceptable salt thereof, wherein constituent members are provided hereinwith. The present invention …

USPTO Abstract

The present invention relates to methods of modulating (for example, inhibiting) activity of JAK3, comprising con-tacting the JAK3 with a compound of Formula I or pharmaceutically acceptable salt thereof, wherein constituent members are provided hereinwith. The present invention further provides novel compounds and compositions as well as their methods of prepara-tion and use of the same as JAK3 inhibitors in the treatment of JAK3-associated diseases including, for example, inflammatory and autoimmune disorders.

Drugs covered by this patent

Patent Metadata

Patent number
CA2752150A1
Jurisdiction
CA
Classification
—
Expires
2010-08-19
Drug substance claim
No
Drug product claim
No
Assignee
Synerga Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.